Literature DB >> 29247986

Biology of IL-38 and its role in disease.

Frank L van de Veerdonk1,2, Dennis M de Graaf1,2, Leo Ab Joosten1,2, Charles A Dinarello1,2.   

Abstract

IL-38 belongs to the IL-36 cytokines, which in turn are part of the IL-1 family. The first biological function of IL-38 described was blocking the activation of the IL-36R signaling similar to IL-36Ra. Since IL-36 cytokines require processing in order to become fully active, it is likely that IL-38 also must be processed to become maximally active. However, the protease(s) responsible for this is currently not known. In addition of IL-38 binding IL-36R, it has been proposed it can also interact with the co-receptor TIGIRR2. IL-38 is expressed in several tissues including tonsils, placenta, heart and brain, and IL-38 has been implicated in a wide variety of diseases including cardiovascular and autoimmune disease. Here, we discuss the discovery and biological function of IL-38, and its role in the pathogenesis of a wide variety of diseases.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-1 family; disease; inflammation; interleukin-38; pathogenesis

Mesh:

Substances:

Year:  2018        PMID: 29247986     DOI: 10.1111/imr.12612

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  26 in total

1.  IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder.

Authors:  Irene Tsilioni; Harry Pantazopoulos; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

Review 2.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

3.  Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma.

Authors:  Xiaoyu Sun; Tianheng Hou; Edwin Cheung; Tiffany Nga-Teng Iu; Victor Wai-Hou Tam; Ida Miu-Ting Chu; Miranda Sin-Man Tsang; Paul Kay-Sheung Chan; Christopher Wai-Kei Lam; Chun-Kwok Wong
Journal:  Cell Mol Immunol       Date:  2019-10-23       Impact factor: 11.530

4.  Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.

Authors:  Ritwik Patra; Nabarun Chandra Das; Suprabhat Mukherjee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  IL-1 Superfamily Members and Periodontal Diseases.

Authors:  E Papathanasiou; P Conti; F Carinci; D Lauritano; T C Theoharides
Journal:  J Dent Res       Date:  2020-08-06       Impact factor: 6.116

Review 6.  Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 7.  Interleukin-36: Structure, Signaling and Function.

Authors:  Li Zhou; Viktor Todorovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 9.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

10.  Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.

Authors:  Dennis M de Graaf; Ralph J A Maas; Sanne P Smeekens; Elan Eisenmesser; Jasmina S Redzic; Monique M Helsen; Nicholas E Powers; Suzhao Li; Vassili Kalabokis; Mark S Gresnigt; Leo A B Joosten; Charles A Dinarello; Frank L van de Veerdonk
Journal:  Cytokine       Date:  2020-10-28       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.